TokenPost·
Xilio Therapeutics Posts $9.98 Million in Q3 2026 Revenue
Collaboration and license revenue was $10.0 million, compared with $19.1 million a year earlier. Net loss per share was $0.30 on both basic and diluted bases.
More news
- TokenPostLimeWire Takes Over Cookie3 and Cookie Pro Operations for InfoFi 2.0 Rebuild
- TokenPostHelius Launches Solana Privacy Rings to Hide On-Chain Asset Details
- TokenPostStrategy Uses $283.8 Million Stock Sale to Fund BTC, STRC Buyback
- Bitcoin MagazineDeutsche Bank Switches On Bitcoin Custody for Paying Clients
- TokenPostKelyniam Global Revenue Rises 35% as Company Returns to Operating Profit
- TokenPostKalaris Posts $0.46 Q3 GAAP Loss Per Share as Net Loss Narrows